Pharmaceuticals

Lentiviral Vector Market Size Forecast: Revenue and CAGR by 2029

November 10, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Global Market Value Of The Lentiviral Vector Industry In 2025?

The lentiviral vector market has observed substantial growth over recent years. It is anticipated to expand from $14.37 billion in 2024 to $16.48 billion in 2025, progressing at a compound annual growth rate (CAGR) of 14.7%. The historical market development can be ascribed to the prevalence of genetic disorders, gene delivery demand, biotech and pharma expansion, clinical trial investment, and regulatory approvals.

The lentiviral vector market is expected to witness substantial expansion over the next few years, with its valuation projected to reach $27.71 billion by 2029, growing at a compound annual growth rate (CAGR) of 13.9%. This growth during the forecast period is attributed to several key drivers, including personalized medicine growth, gene editing innovations, rare disease therapy demand, lentiviral vector adoption, genomic medicine funding, and manufacturing scalability focus. Significant trends anticipated within the forecast period include the expansion of research and development, integration in CAR-T cell therapy, development of next-generation vectors, adoption in vaccine development, and development of production technologies.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=14742&type=smp

What Are The Top Growth Drivers Impacting The Lentiviral Vector Market Outlook?

The lentiviral vectors market is projected to grow due to the rising occurrence of chronic illnesses. These are defined as enduring medical conditions that typically advance gradually and often persist for many years or even a lifetime. The escalating prevalence of chronic diseases is attributed to an aging global demographic, unhealthy lifestyle choices, increasing urbanization, and various environmental elements. Lentiviral vectors offer adaptable and potent instruments for the development of vaccines and therapeutic approaches for chronic diseases, thereby addressing critical medical requirements and enhancing patient outcomes. For instance, in September 2024, data from the British Heart Foundation, a UK-based cardiovascular research charity, revealed that in the UK, approximately 7.6 million individuals are impacted by heart and circulatory diseases, with around 4 million males and 3.6 million females living with these ailments. These conditions contribute to approximately 27% of all deaths in the UK, translating to over 170,000 annual fatalities, or roughly 480 deaths each day, equating to one death every three minutes. Consequently, the escalating incidence of chronic diseases is stimulating the expansion of the lentiviral vectors market.

What Are The Key Segments In The Lentiviral Vector Market?

The lentiviral vector market covered in this report is segmented –

1) By Product Type: Kits, Reagents And Consumables

2) By Indication: Cancer, Genetic Disorder, Infectious Disease, Veterinary Disease, Other Indications

3) By End User: Biotechnology Companies, Pharmaceutical Companies, Contract Research Organization (CRO), Academic And Research Institutes

Subsegments:

1) By Kits: Lentiviral Transduction Kits, Lentiviral Packaging Kits, Lentiviral Vector Production Kits

2) By Reagents and Consumables: Lentiviral Packaging Reagents, Lentiviral Vector Concentration Reagents, Transfection Reagents for Lentiviral Vectors

Which Market Trends Are Creating New Opportunities In The Lentiviral Vector Industry?

Major companies operating within the lentiviral vectors market are concentrating on developing LV vector production platforms, exemplified by LentiSure, to elevate the efficiency and resilience of producing lentivirus vectors for cell-based immuno-oncology therapies. LentiSure functions as an LV vector production platform that generates lentiviral vectors utilized in cell-based immuno-oncology therapies, specifically designed to enhance their production’s efficiency and robustness. For instance, in May 2023, Yposkesi sk pharmteco, a viral vector manufacturer based in France, introduced LentiSure, an advanced platform engineered to improve the output of lentiviral (LV) vectors and thereby bolster the resilience and efficiency of lentivirus production. This platform directly addresses the expanding requirement for robust and economically scalable viral-vector manufacturing technologies in cell and gene therapies. It ensures consistent product quality, with average titers at cell culture harvest reaching 10e7 IG/mL bioreactor volume, which contributes to higher productivity and improved success for cell therapy developers.

Who Are The Core Companies Influencing The Lentiviral Vector Market Landscape?

Major companies operating in the lentiviral vector market are Pfizer Inc., AbbVie Inc., Bayer AG, Sanofi SA, Bristol Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca plc, Novartis AG, GlaxoSmithKline plc (GSK), Eli Lilly and Company, Agilent Technologies Inc., Amgen Inc., Merck KGaA, Lonza Group Ag, Cytiva, Charles River Laboratories, Bio-Rad Laboratories Inc., Promega Corporation, Takara Bio Inc., Sino Biological Inc., OriGene Technologies Inc., Applied Biological Materials Inc., Oxford Biomedica, Sirion-Biotech GmbH, Yposkesi

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/lentiviral-vector-global-market-report

How Is Lentiviral Vector Market Demand Varying Across Different Regions?

North America was the largest region in the lentiviral vector market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lentiviral vector market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Request A Customized Version Of The Lentiviral Vector Market Report:

https://www.thebusinessresearchcompany.com/customise?id=14742&type=smp

Browse Through More Reports Similar to the Global Lentiviral Vector Market 2025, By The Business Research Company

Viral Vectors And Plasmid Dna Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/viral-vectors-and-plasmid-dna-global-market-report

Bacterial And Plasmid Vector Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/bacterial-and-plasmid-vector-global-market-report

Vector Control Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/vector-control-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795